全文获取类型
收费全文 | 3622篇 |
免费 | 194篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 64篇 |
妇产科学 | 48篇 |
基础医学 | 502篇 |
口腔科学 | 43篇 |
临床医学 | 442篇 |
内科学 | 796篇 |
皮肤病学 | 32篇 |
神经病学 | 355篇 |
特种医学 | 90篇 |
外科学 | 426篇 |
综合类 | 20篇 |
一般理论 | 1篇 |
预防医学 | 334篇 |
眼科学 | 95篇 |
药学 | 276篇 |
中国医学 | 1篇 |
肿瘤学 | 260篇 |
出版年
2023年 | 20篇 |
2022年 | 46篇 |
2021年 | 73篇 |
2020年 | 45篇 |
2019年 | 45篇 |
2018年 | 52篇 |
2017年 | 45篇 |
2016年 | 76篇 |
2015年 | 97篇 |
2014年 | 115篇 |
2013年 | 148篇 |
2012年 | 227篇 |
2011年 | 267篇 |
2010年 | 132篇 |
2009年 | 176篇 |
2008年 | 260篇 |
2007年 | 294篇 |
2006年 | 311篇 |
2005年 | 304篇 |
2004年 | 224篇 |
2003年 | 213篇 |
2002年 | 180篇 |
2001年 | 26篇 |
2000年 | 20篇 |
1999年 | 23篇 |
1998年 | 44篇 |
1997年 | 33篇 |
1996年 | 39篇 |
1995年 | 22篇 |
1994年 | 24篇 |
1993年 | 38篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 12篇 |
1989年 | 12篇 |
1988年 | 15篇 |
1987年 | 8篇 |
1986年 | 12篇 |
1984年 | 5篇 |
1983年 | 11篇 |
1982年 | 9篇 |
1981年 | 5篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1973年 | 4篇 |
1943年 | 3篇 |
1940年 | 3篇 |
1935年 | 4篇 |
1932年 | 8篇 |
1931年 | 3篇 |
排序方式: 共有3824条查询结果,搜索用时 0 毫秒
71.
Lem AJ de Rijke YB van Toor H de Ridder MA Visser TJ Hokken-Koelega AC 《The Journal of clinical endocrinology and metabolism》2012,97(9):3170-3178
Context: Age-appropriate reference ranges for thyroid hormones are required for detecting pediatric thyroid dysfunction. Data on thyroid hormones and peripheral thyroid metabolism in short children born small for gestational age (SGA) before and during GH treatment are lacking. Objectives: Our objectives were to obtain pediatric thyroid hormone reference ranges; to investigate thyroid hormones in short SGA children before puberty, during puberty, and during postponement of puberty by GnRH analog; and to evaluate thyroid hormones during GH treatment. Patients and Design: In 512 healthy children (225 females; 0-18 yr), free T(4) (FT(4)), TSH, total T(4), T(3), rT(3), and T(4)-binding globulin were determined. Reference ranges were calculated using the linearity, median, and skewness method. In 125 short SGA children (62 females; mean age 11.3 yr), thyroid hormones were analyzed before and after 2 yr of GH treatment and additional GnRH analog. Results: Thyroid references showed wide ranges postnatally and age-specific patterns thereafter, similar in boys and girls. Untreated short SGA children had similar FT(4) and T(4) levels as the reference population but significantly higher T(3), rT(3), and T(4)-binding globulin levels. During puberty and during GH treatment, FT(4) and rT(3) significantly decreased, whereas T(3) significantly increased. Conclusion: Age-specific thyroid reference ranges are presented. Puberty and GH treatment both induce changes in peripheral thyroid metabolism, resulting in more biologically active T(3) at the expense of less inactive rT(3), possibly mediated by IGF-I. GH treatment induces altered peripheral thyroid metabolism but does not result in thyroid dysfunction. 相似文献
72.
73.
74.
Meurs I Lammers B Zhao Y Out R Hildebrand RB Hoekstra M Van Berkel TJ Van Eck M 《Atherosclerosis》2012,221(1):41-47
ObjectiveAs ABCG1 plays a role in cholesterol efflux, macrophage ABCG1 expression has been suggested to protect against atherosclerosis. However, we and others observed varying effects of ABCG1 deficiency on atherosclerotic lesion size. The objective of this study was to define the effect of ABCG1 deficiency during atherosclerotic lesion progression in LDL receptor knockout (LDLr?/?) mice.Methods and resultsABCG1?/?/LDLr?/? and ABCG1+/+/LDLr?/? littermates were fed a Western-type diet for 10 and 12 weeks in order to study the effect of ABCG1 deficiency in the exponential phase of atherosclerotic lesion formation. At 10 weeks of diet feeding, a significant 1.5-fold increase in early atherosclerotic lesion size (130 ± 12 × 103 μm2) was observed in ABCG1?/?/LDLr?/? mice compared to ABCG1+/+/LDLr?/? mice (88 ± 11 × 103 μm2; p < 0.05). Interestingly, in more advanced lesions, induced by 12 weeks of WTD feeding, ABCG1?/?/LDLr?/? mice showed a significant 1.7-fold decrease in atherosclerotic lesion size (160 ± 20 × 103 μm2 vs 273 ± 19 × 103 μm2 in control mice; p < 0.01), indicating that in the ABCG1?/?/LDLr?/? mice progression of lesion formation is retarded as compared to ABCG1+/+/LDLr?/? mice. In addition, correlation analysis performed on 7 independent published studies and the current study confirmed that ABCG1 is atheroprotective in early lesions, while the development of advanced lesions is stimulated.ConclusionsIt appears that the effect of ABCG1 deficiency on lesion development in LDLr?/? mice depends on the stage of atherogenesis, whereby the absence of ABCG1 leads to increased lesions at sizes < 167 × 103 μm2 while in more advanced stages of atherosclerosis enhanced apoptosis and/or compensatory mechanisms lead to retarded lesion progression. 相似文献
75.
76.
77.
78.
Fiona?J?CharlsonEmail author Andrew?E?Moran Greg?Freedman Rosana?E?Norman Nicolas?JC?Stapelberg Amanda?J?Baxter Theo?Vos Harvey?A?Whiteford 《BMC medicine》2013,11(1):250
Background
Cardiovascular disease and mental health both hold enormous public health importance, both ranking highly in results of the recent Global Burden of Disease Study 2010 (GBD 2010). For the first time, the GBD 2010 has systematically and quantitatively assessed major depression as an independent risk factor for the development of ischemic heart disease (IHD) using comparative risk assessment methodology.Methods
A pooled relative risk (RR) was calculated from studies identified through a systematic review with strict inclusion criteria designed to provide evidence of independent risk factor status. Accepted case definitions of depression include diagnosis by a clinician or by non-clinician raters adhering to Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) classifications. We therefore refer to the exposure in this paper as major depression as opposed to the DSM-IV category of major depressive disorder (MDD). The population attributable fraction (PAF) was calculated using the pooled RR estimate. Attributable burden was calculated by multiplying the PAF by the underlying burden of IHD estimated as part of GBD 2010.Results
The pooled relative risk of developing IHD in those with major depression was 1.56 (95% CI 1.30 to 1.87). Globally there were almost 4 million estimated IHD disability-adjusted life years (DALYs), which can be attributed to major depression in 2010; 3.5 million years of life lost and 250,000 years of life lived with a disability. These findings highlight a previously underestimated mortality component of the burden of major depression. As a proportion of overall IHD burden, 2.95% (95% CI 1.48 to 4.46%) of IHD DALYs were estimated to be attributable to MDD in 2010. Eastern Europe and North Africa/Middle East demonstrate the highest proportion with Asia Pacific, high income representing the lowest.Conclusions
The present work comprises the most robust systematic review of its kind to date. The key finding that major depression may be responsible for approximately 3% of global IHD DALYs warrants assessment for depression in patients at high risk of developing IHD or at risk of a repeat IHD event.79.
Gorlani A Brouwers J McConville C van der Bijl P Malcolm K Augustijns P Quigley AF Weiss R De Haard H Verrips T 《AIDS research and human retroviruses》2012,28(2):198-205
There is an urgent global need for preventive strategies against HIV-1 infections. Llama heavy-chain antibody fragments (VHH) are a class of molecules recently described as potent cross-clade HIV-1 entry inhibitors. We studied the potential of a VHH-based microbicide in an application-oriented fashion. We show that VHH can be inexpensively produced in high amounts in the GRAS organism Saccharomyces cerevisiae, resulting in a very pure and endotoxin free product. VHH are very stable under conditions they might encounter during transport, storage, or use by women. We developed active formulations of VHH in aqueous gel and compressed and lyophilized tablets for controlled release from an intravaginal device. The release profile of the VHH from, e.g., a vaginal ring suggests sufficient bioavailability and protective concentration of the molecule at the mucosal site at the moment of the infection. The ex vivo penetration kinetics through human tissues show that the VHH diffuse into the mucosal layer and open the possibility to create a second defense layer either by blocking the HIV receptor binding sites or by blocking the receptors of immune cells in the mucosa. In conclusion, our data show that VHH have a high potential for HIV-1 microbicide application because of their low production costs, their high stability, and their favorable release and tissue penetration properties. 相似文献
80.